Design and synthesis of novel indole β-diketo acid derivatives as HIV-1 integrase inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 21, 2004, Pages 5298-5310

  Sechi, Mario ^a   Derudas, Massimiliano ^a   Dallocchio, Roberto ^b   Dessì, Alessandro ^b   Bacchi, Alessia ^c   Sannia, Luciano ^a   Carta, Fabrizio ^a   Palomba, Michele ^a   Ragab, Omar ^d   Chan, Carney ^d   Shoemaker, Robert ^e   Sei, Shizuko ^f   Dayam, Raveendra ^d   Neamati, Nouri ^d  

^a UNIVERSITY OF SASSARI   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Screening Technologies Branch   (United States)

^f SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 4 (1 METHYL 1H INDOL 2 YL) 4 OXOBUT 2 ENOIC ACID; 2 HYDROXY 4 (1 METHYL 1H INDOL 3 YL) 4 OXOBUT 2 ENOIC ACID; 2 HYDROXY 4 (5 METHYL 5H [1,3]DIOXOLO[4,5 F]INDOL 6 YL) 4 OXOBUT 2 ENOIC ACID; 2 HYDROXY 4 (5 METHYL 5H [1,3]DIOXOLO[4,5 F]INDOL 7 YL) 4 OXOBUT 2 ENOIC ACID; 4 (1 BENZYL 1H INDOL 2 YL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 (1 BENZYL 1H INDOL 3 YL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 (1 ETHYL 1H INDOL 2 YL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 (1 ETHYL 1H INDOL 3 YL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 (5 BENZYL 5H [1,3]DIOXOLO[4,5 F]INDOL 6 YL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 (5 ETHYL 5H [1,3]DIOXOLO[4,5 F]INDOL 6 YL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; 4 (5 ETHYL 5H [1,3]DIOXOLO[4,5 F]INDOL 7 YL) 2 HYDROXY 4 OXOBUT 2 ENOIC ACID; INDOLE BETA DIKETO ACID DERIVATIVE; INTEGRASE; INTEGRASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INDOLES; KETO ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 4744348464     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049944f     Document Type: Article

References (64)

1. De Clercq, E. New developments in anti-HIV chemotherapy. Biochim. Biophys. Acta 2002, 1587, 258-275.
2. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discovery 2002, 1, 13-25.
3. Richman, D. D. HIV chemotherapy. Nature 2001, 410, 995-1001.
4. Bushman, F. D.; Craigie, R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1339-1343.
5. Brown, P. O. Integration; Cold Spring Harbor Press: Cold Spring Harbor, 1999.
6. Asante-Appiah, E.; Skalka, A. M. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 1999, 52, 351-369.
7. Engelman, A.; Mizuuchi, K.; Craigie, R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991, 67, 1211-1221.
8. Neamati, N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Exp. Opin. Invest. Drugs 2001, 10, 281-296.
9. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: a ten-year saga. Exp. Opin. Ther. Pat. 2002, 12, 709-724.
10. Dayam, R.; Neamati, N. Small-molecule HIV-1 integrase inhibitors: The 2001-2002 update. Curr. Pharm. Des. 2003, 9, 1789-1802.
11. Pais, G. C. G.; Burke, T. R. Novel aryl diketo-containing inhibitors of HIV-1 integrase. Drugs Future 2002, 27, 1101-1111.
12. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.
13. Herr, R. J. 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods. Bioorg. Med. Chem. 2002, 10, 3379-3393.
14. Espeseth, A. S.; Felock, P.; Wolfe, A.; Witmer, M.; Grobler, J.; Anthony, N.; Egbertson, M.; Melamed, J. Y.; Young, S.; Hamill, T.; Cole, J. L.; Hazuda, D. J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 11244-11249.
15. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
16. Wai, J. S.; Egbertson, M. S.; Payne, L. S.; Fisher, T. E.; Embrey, M. W.; Tran, L. O.; Melamed, J. Y.; Langford, H. M.; Guare, J. P., Jr.; Zhuang, L.; Grey, V. E.; Vacca, J. P.; Holloway, M. K.; Naylor-Olsen, A. M.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Schleif, W. A.; Gabryelski, L. J.; Young, S. D. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem. 2000, 43, 4923-4926.
17. Pais, G. C.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E. S.; Pathak, V. K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T. R., Jr. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J. Med. Chem. 2002, 45, 3184-3194.
18. Barret, C. B.; Beer, J. R.; Dodd, G. M.; Robertson, A. The chemistry of bacteria. Part VI. The synthesis of a trimethyl derivative of the C20 acid from violacein. J. Chem. Soc. 1957, 4810-4813.
19. Kawai, H.; Kitano, Y.; Mutoh, M.; Hata, G. Synthesis, structure and antitumor activity of a new water-soluble platinum complex, (1R,2R- cyclohexanediamine-N,N′)[2-hydroxy-4-oxo-2-pentenoato-(2-)-O2]platinum(II) . Chem. Pharm Bull. (Tokyo) 1993, 41, 357-361.
20. Haeney, H.; Ley, S. V. N-alkylation of indole and pyrroles in dimethyl sulphoxide. J. Chem. Soc., Perkin Trans. 1 1973, 499-500.
21. Bennasar, M.-L.; Vidal, B.; Bosch, J. Biomimetic total synthesis of ervitsine and indole alkaloids of the ervatamine group via 1,4-dihydropyridines. J. Org. Chem. 1997, 62, 3597-3609.
22. Hemetsberger, H.; Knittel, D.; Weidmann, H. Enazides, Part 3: Thermolysis of a-azidocinnamates; synthesis of indole derivatives. Monatsch. Chem. 1970, 101, 161-165.
23. Knittel, D. Improved synthesis of a-azidocinnamates and 2H-azirines. Synthesis 1985, 186-188.
24. Murakami, Y.; Tani, M.; Suzuki, M.; Sudoh, K.; Uesato, M.; Tanaka, K.; Yokoyama, Y. Synthetic studies on indoles and reated compounds. XII. A simple general method for the G3 acylation of ethyl indole-2-carboxylate. Chem. Pharm. Bull. 1985, 33, 4707-4716.
25. Kalinowski, H. O.; Berger, S.; Braun, S. Carbon-13 NMR Spectroscopy; John Wiley & Sons: New York, 1991; p 197.
26. Pretsch, E.; Seibl, J.; Simon, W. Tables of Spectral Data for Structure Determination of Organic Compounds; Springer-Verlag: Berlin, 1989.
27. Bertolasi, V.; Gilli, P.; Ferretti, V.; Gilli, G. Evidence for resonance-assisted hydrogen bonding. 2. Intercorrelation between crystal structure and spectroscopic parameters in eight intramolecularly hydrogen bonded 1,3-diaryl-1,3-propanedione enols. J. Am. Chem. Soc. 1991, 113, 4917-4925.
28. Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A. S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J. S.; Young, S.; Vacca, J.; Hazuda, D. J. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6661-6666.
29. Steitz, T. A. A mechanism for all polymerases. Nature 1998, 391, 231-232.
30. Long, Y. Q.; Jiang, X. H.; Dayam, R.; Sanchez, T.; Shoemaker, R.; Sei, S.; Neamati, N. Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: Implication for binding to two metal ions on the active site of integrase. J. Med. Chem. 2004, 47, 2561-2573.
31. Sotriffer, C. A.; Ni, H.; McCammon, A. J. HIV-1 Integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. J. Am. Chem. Soc. 2000, 122, 6136-6137.
32. Sotriffer, C. A.; Ni, H.; McCammon, J. A. Active site binding modes of HIV-1 integrase inhibitors. J. Med. Chem. 2000, 43, 4109-4117.
33. Ni, H.; Sotriffer, C. A.; McCammon, J. A. Ordered water and ligand mobility in the HIV-1 integrase-5CITEP complex: a molecular dynamics study. J. Med. Chem. 2001, 44, 3043-3047.
34. Barreca, M. L.; Lee, K. W.; Chimirri, A.; Briggs, J. M. Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: Mechanism for inhibition and drug resistance. Biophys. J. 2003, 84, 1450-1463.
35. Lins, R. D.; Straatsma, T. P.; Briggs, J. M. Similarities in the HIV-1 and ASV integrase active sites upon metal cofactor binding [in process citation]. Biopolymers 2000, 53, 308-315.
36. Lins, R. D.; Adesokan, A.; Soares, T. A.; Briggs, J. M. Investigations on human immunodeficiency virus type 1 integrase/DNA binding interactions via molecular dynamics and electrostatics calculations. Pharmacol. Ther. 2000, 85, 123-131.
37. Lins, R. D.; Briggs, J. M.; Straatsma, T. P.; Carlson, H. A.; Greenwald, J.; Choe, S.; McCammon, J. A. Molecular dynamics studies on the HIV-1 integrase catalytic domain. Biophys. J. 1999, 76, 2999-3011.
38. Schames, J. R.; Henchman, R. H.; Siegel, J. S.; Sotriffer, C. A.; Ni, H.; McCammon, J. A. Discovery of a novel binding trench in HIV integrase. J. Med. Chem. 2004, 47, 1879-1881.
39. Neamati, N.; Marchand, C.; Pommier, Y. HIV-1 integrase inhibitors: Past, present, and future. Adv. Pharmacol. 2000, 49, 147-165.
40. Neamati, N.; Barchi, J. J., Jr. New paradigms in drug design and discovery. Curr. Top. Med. Chem. 2002, 2, 211-227.
41. Sechi, M.; Sannia, L.; Orecchioni, M.; Carta, F.; Paglietti, G.; Neamati, N. Structural investigation of 3,5-disubstituted isoxazoles by H-1-nuclear magnetic resonance. J. Heterocycl. Chem. 2003, 40, 1097-1102.
42. Sechi, M.; Angotzi, G.; Dallocchio, R.; Dessì, A.; Carta, F.; Sannia, L.; Mariani, A.; Fiori, S.; Sanchez, T.; Movssessian, L.; Plasencia, C.; Neamati, N. Design and synthesis of novel dihydroxyindole-2-carboxylic acids as HIV-1 integrase inhibitors. Antiviral Chem. Chemother. 2004, 15, 95-109.
43. Ottoni, O.; Cruz, R.; Alves, R. Efficient and simple methods of the introduction of the sulphonyl, acyl and alkyl protecting group on the nitrogen of indole and its derivatives. Tetrahedron 1998, 54, 13915-13928.
44. Anthony, C. W. Novel synthesis of heterocyclic ketones. J. Org. Chem. 1960, 25, 2049-2053.
45. Johnson, J. R.; Hasbrouck, R. B.; Dutcher, J. D.; Bruce, W. F. Gliotoxin. The structure of certain indole derivatives relate to gliotoxin. J. Am. Chem. Soc. 1945, 67, 423-430.
46. Fagan, G. P.; Chapleo, C. B.; Lane, A. C.; Myers, M.; Roach, A. G.; Smith, C. F.; Stillings, M. R.; Welbourn, A. P. Indoline analogues of idazoxan: potent α2-antagonists and α1-agonists. J. Med. Chem. 1988, 31, 944-948.
47. Daou, B.; Soufiaoui, M. Nouvelle voie de synthese d'arylpyrazolo-[4,3-c] quinoleines via la cycloaddition dipolaire-1, -3. Tetrahedron 1989, 45, 3351-3361.
48. Olgen, S.; Akaho, E.; Nebioglu, D. Synthesis and receptor docking studies of N-substituted indole-2-carboxylic acid esters as a search for COX-2 selective enzyme inhibitors. Eur. J. Med. Chem. 2001, 36, 747-770.
49. Hlasta, J. D.; Court, J. J. Tandem organometallic addition reactions to N-methoxy-ureas and urethanes in tha preparation of unsymmetrical and symmetrical ketones. Tetrahedron Lett. 1989, 30, 1773-1776.
50. Ferrer, P.; Avendaño, C.; Söllhuber, M. Synthesis of 5,8-dimethoxy-2(1H)-quinolinones by intramolecular Witting reaction. Justus Liebigs Ann. Chem. 1995, 2, 1895-1899.
51. Barry, J. F.; Wallace, W. W.; Walshe, N. D. A. On the [4+2] cycloaddition approach to indolo[2,3-a]carbazoles. Tetrahedron 1995, 51, 12797-12806.
52. SAINT: SAX, A. D. I.; Siemens Analytical Instruments Inc.: Madison, WI.
53. SADABS: Siemens Area Detector Absorption Correction Software, S. G.; University of Goettingen: Germany, 1996.
54. Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A. G.; Polidori, G.; Spagna, R. Sir97: A New Program For Solving And Refining Crystal Structures; Istituto di Ricerca per lo Sviluppo di Metodologie Cristallografiche CNR: Bari, 1997.
55. Sheldrick, G. M. SHELXL 97: Program for the Refinement of Crystal Structures; University of Göttingen: Germany, 1997.
56. Weislow, O. W.; Kiser, R.; Fine, D.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
57. Catalyst, V.4.7; Accelrys, I.: San Diego.
58. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of conformational coverage. 1. Validation and estimation of coverage. J. Chem. Inf. Comput. Sci. 1995, 35, 285-294.
59. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of conformational coverage. 2. Application of conformational models. J. Chem. Inf. Comput. Sci. 1995, 35, 295-304.
60. Smellie, A.; Teig, S. L.; Towbin, P. Poling - promoting conformational variation. J. Comput. Chem. 1995, 16, 171-187.
61. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9150-9154.
62. GOLD Cambridge Crystallographic Data Centre (CCDC), V1.2; United Kingdom, 2001.
63. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
64. Nissink, J. W.; Murray, C.; Hartshorn, M.; Verdonk, M. L.; Cole, J. C.; Taylor, R. A new test set for validating predictions of protein - ligand interaction. Proteins 2002, 49, 457-471.